SELLAS Life Sciences stock climbs 12% after two-session decline SELLAS Life Sciences Group stock rebounded on Friday with a 12% gain. The company is a late-stage clinical biopharmaceutical firm developing cancer therapeutics. The stock's rebound came after
SELLAS Life Sciences stock climbs 12% after two-session decline
SELLAS Life Sciences Group stock rebounded on Friday with a 12% gain.
The company is a late-stage clinical biopharmaceutical firm developing cancer therapeutics.
The stock’s rebound came after two consecutive days of decline.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
